• LAST PRICE
    6.7500
  • TODAY'S CHANGE (%)
    Trending Down-0.1300 (-1.8895%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    6.8640 / 6.8800
  • Day Range
    Low 6.7500
    High 6.8640
  • 52 Week Range
    Low 2.9800
    High 10.5100
  • Volume
    15,058
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 6.88
TimeVolumeIDXG
10:26 ET2006.86
10:27 ET2006.85
10:33 ET7006.81
11:16 ET1006.81
12:39 ET3506.76
12:42 ET5006.83
12:50 ET2366.76
01:00 ET2006.76
01:09 ET1756.8
01:22 ET3506.8
01:31 ET5006.8
01:44 ET3506.8
01:51 ET1756.8
02:00 ET4256.8
02:02 ET33006.8
02:03 ET1756.78
02:14 ET2006.78
02:23 ET6716.76
02:36 ET2006.76
02:45 ET1756.76
02:57 ET2006.76
03:08 ET2006.76
03:17 ET2006.76
03:35 ET2006.76
03:39 ET2006.76
03:48 ET6006.8
03:50 ET3506.75
04:00 ET19806.75
Data delayed at least 15 minutes.

Jan 12, 2022

Jan 3, 2022

0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIDXG
Interpace Biosciences Inc
28.9M
-1.4x
---
United StatesALHC
Alignment Healthcare Inc
1.4B
-7.4x
---
United StatesPGNY
Progyny Inc
3.5B
42.6x
---
United StatesGTS
Triple-S Management Corp
846.6M
10.2x
+8.41%
United StatesMOH
Molina Healthcare Inc
16.4B
27.9x
+34.44%
United StatesHUM
Humana Inc
48.6B
18.5x
+24.56%
As of 2022-01-20

Company Information

Interpace Biosciences, Inc. is an independent molecular diagnostics and biopharma services company. The Company is focused on providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. It offers services along with the therapeutic value chain from early diagnosis and prognostic planning to target therapeutic applications through its clinical and pharma services. Its clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other services to the pharmaceutical and biotech industries. The Company's products include ThyGenNEXT, ThyraMIR, PancraGEN, RespriDX and BarreGen.

Contact Information

Headquarters
Morris Corporate Center 1 , Building C, 300 Interpace ParkwayPARSIPPANY, NJ, United States 07054
Phone
412-224-6100
Fax
302-636-5454

Executives

President, Chief Executive Officer, Director
Thomas Burnell
Chief Financial Officer, Treasurer, Company Secretary
Thomas Freeburg
Director
Robert Gorman
Independent Director
Edward Chan
Independent Director
Joseph Keegan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$28.9M
Revenue (TTM)
$40.1M
Shares Outstanding
4.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.02
EPS
$-4.91
Book Value
$4.30
P/E Ratio
-1.4x
Price/Sales (TTM)
0.7
Price/Cash Flow (TTM)
---
Operating Margin
-46.52%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.